.jpg)
Taiho buys Swiss biotech and its ADC tech for $400M
The pharma will acquire Araris Biotech to gain access to a trio of preclinical ADCs and a linking technology Araris claims is superior to conventional platforms.
The pharma will acquire Araris Biotech to gain access to a trio of preclinical ADCs and a linking technology Araris claims is superior to conventional platforms.
